Copyright and Disclaimer Print  


Alberta Regulation 18/2005
Cancer Programs Act
CANCER PROGRAMS AMENDMENT REGULATION
Filed: February 22, 2005
For information only:   Made by the Minister of Health and Wellness (M.O. 9/2005) 
on February 17, 2005 pursuant to sections 16 and 22 of the Cancer Programs Act. 
1   The Cancer Programs Regulation (AR 242/98) is 
amended by this Regulation.

2   The Schedule is repealed and the following Schedule is 
substituted:
Schedule

Drug
Group
Dosage 
Form 

Criteria
13 Cis-RETINOIC ACID
2
capsules
Pediatrics 
- restricted to the treatment 
of advanced stage 
neuroblastoma following 
POG/CCG Protocols 
 - prescribing limited to 
written authorization by 
physicians recommended by 
the pediatric tumour program
ALL-TRANS RETINOIC ACID
2
capsules
 - restricted to treatment of 
acute promyelocytic 
leukemia 
 - prescribing limited to 
written authorization by 
physicians recommended by 
the hematology/lymphoma 
tumour program or the 
pediatric tumour program
AMSACRINE
2
injectable

ANAGRELIDE
1
capsules
 - for thrombocytosis due to 
myeloproliferative disorder 
 - prescribing limited to 
written authorization by 
physicians recommended by 
the hematology/lymphoma 
tumour program
ANASTROZOLE
1
tablets
 - for post-menopausal 
patients with receptor-
positive, metastatic breast 
cancer who have progressed 
or have experienced severe 
side effects on prior hormone 
therapy

2
tablets
Breast Cancer Adjuvant 
 - for adjuvant use in invasive 
breast cancer patients who 
are post-menopausal, 
hormone receptor positive in 
whom tamoxifen is 
contraindicated or not 
tolerated 
 - prescribing limited to 
written authorization by 
named physicians as 
recommended by the breast 
tumour program
ASPARAGINASE
1
injectable

BCG
1
injectable
 - bladder carcinoma
BICALUTAMIDE
1
tablets
 - restricted to patients who 
are intolerant to Nilutamide 
or Flutamide 
 - approved dosage is 50 mg 
daily
BLEOMYCIN
1 
2
injectable 
pump

BUSERELIN
1
injectable
- prostate cancer 
 - Restricted to: 
Stage II (T2a-T2c): 
Neoadjuvant use pre RT (2 
months pre and during RT). 
Neoadjuvant use pre radical 
prostatectomy (4 months pre) 
Stage III (T3a-T4b): 
Neoadjuvant use pre RT (2 
months pre and during RT). 
Adjuvant use (3 years post 
RT)



Stage IV (N1-N3) 
(M1-M1c): As monotherpy 
in medical castration. 
In total androgen blockade 
(medical castration and 
nonsteriodal antiandrogen)



 - Guidelines for LHRH use 
in the above stated stages 
include: LHRH agonists are 
indicated for use in patients 
at risk of thromboembolic 
disease, strokes (CVA), 
myocardial infarction and 
also for consideration in 
patients with dyslipidemia, 
hypertension, diabetes 
mellitus or where a patient is 
considered intolerant to 
cyproterone acetate or 
megestrol acetate
BUSULFAN
1
tablets

CAPECITABINE
2
oral
 - metastatic or advanced 
breast cancer (with or 
without prior anthracycline 
exposure) 
 - prescribing limited to 
written authorization by 
physicians recommended by 
the breast tumour program

2
oral
 - option in first line 
treatment of advanced or 
metastatic colorectal cancer 
 - prescribing limited to 
written authorization by 
named physicians as 
recommended by the GI 
tumour program

2
oral
- adjuvant treatment of colon 
cancer 
- prescribing limited to 
written authorization by 
named physicians as 
recommended by the GI 
tumour program
CARBOPLATIN
1
injectable

CARMUSTINE
1
injectable, 
topical

CHLORAMBUCIL
1
tablets

CISPLATIN
1
injectable

CLADRIBINE
2
injectable, 
subcutane-
ous
 - restricted to treatment of 
hairy cell leukemia 
 - Waldenstrom's 
macroglobulinemia 
 - hematologic malignancies 
(histocytosis-X, cutaneous 
T-cell lymphoma, systemic 
mast cell disease) 
 - prescribing limited to 
written authorization by 
physicians recommended by 
the hematology/lymphoma 
tumour program

3
injectable
POG Protocol 9720 
prescribing limited to written 
authorization by physicians 
recommended by the 
pediatric tumour program
CLODRONATE
1
oral
 - treatment of osteolytic 
bone lesions in metastatic 
breast cancer
CYCLOPHOSPHAMIDE
1
injectable, 
tablets

CYPROTERONE
1
tablets

CYTARABINE
1
injectable

CYTARABINE LIPOSOMAL
3
injectable
 - for intrathecal management 
of neoplastic meningitis due 
to solid tumours or 
lymphoma
DACARBAZINE
1
injectable

DACTINOMYCIN
1
injectable

DAUNORUBICIN
1
injectable

DEXAMETHASONE
1
injectable, 
tablets
 - antiemetic use NOT 
covered
DOCETAXEL
2
injectable
 - treatment of metastatic 
breast cancer after failure of 
any previous chemotherapy 
regimen 
- as a single agent or in 
combination, as an option for 
first line treatment of 
metastatic breast cancer 
 - only one taxane is to be 
administered to any one 
patient 
 - prescribing limited to 
written authorization by 
named physicians as 
recommended by the breast 
tumour program

2
injectable
Breast Neoadjuvant 
 - following a neoadjuvant 
anthracycline containing 
regimen in locally advanced 
(Stage IIIA or IIIB) breast 
cancer 
 - prescribing limited to 
written authorization by 
named physicians as 
recommended by the breast 
tumour program

2
injectable
Breast Adjuvant 
 - (with doxorubicin and 
cyclophosphamide (TAC)) 
for adjuvant treatment of 
node positive breast cancer 
 - prescribing limited to 
written authorization by 
named physicians as 
recommended by the breast 
tumour program

2
injectable
 - 2nd line therapy in patients 
with advanced or metastatic 
non-small cell lung cancer 
with good performance status 
(ECOG 0-2) and no 
symptomatic or uncontrolled 
brain metastases 
 - prescribing limited to 
written authorization by 
named physicians as 
recommended by the lung 
tumour program

2
injectable
Prostate Cancer 
- Docetaxel (with 
prednisone) as first-line 
treatment of hormone 
refractory prostate cancer 
- prescribing limited to 
written authorization by 
named physicians as 
recommended by the tumour 
program
DOXORUBICIN
1
injectable

DOXORUBICIN LIPOSOMAL
2
injectable
 - Kaposi's sarcoma

2
injectable
 - 2nd or 3rd line treatment of 
ovarian cancer, fallopian tube 
carcinoma and primary 
peritoneal neoplasms 
 - prescribing limited to 
written authorization by 
named physicians as 
recommended by the 
gynecology tumour program
EPIRUBICIN
2
injectable
Breast Cancer 
 - adjuvant (node positive) 
and neoadjuvant (stage II and 
III) treatment of pre- and 
post-menopausal breast 
cancer patients 
- adjuvant treatment of high 
risk (as defined by current 
Alberta Breast Cancer 
Program Guidelines), lymph 
node negative breast cancer 



- prescribing limited to 
written authorization by 
named physicians as 
recommended by the breast 
tumour program

2
injectable
Esophagogastric Cancer 
 - used (in combination with 
cisplatin and fluorouracil) in 
the treatment of locally 
advanced or metastatic 
esophagogastric cancer in 
patients with good 
performance status

3
injectable
NCIC MA21 Trial 
 - use as adjuvant treatment 
in NCIC MA21 Trial 
 - prescribing limited to 
written authorization by 
clinical trial principal 
investigator(s) or co-
investigators
ESTRAMUSTINE
1
capsules

ETOPOSIDE
1
injectable, 
capsules

EXEMESTANE
1
oral
 - for post-menopausal 
patients with 
receptor-positive, 
advanced/metastatic breast 
cancer that have progressed 
or have experienced severe 
side effects on prior hormone 
therapy
FLUDARABINE
2
injectable, 
tablets
 - previously treated or 
untreated chronic 
lymphocytic leukemia 
 - low grade lymphoma 
 - Waldenstrom's 
macroglobulinemia 
 - prescribing limited to 
written authorization by 
physicians recommended by 
the hematology tumour 
program
FLUOROURACIL
1 
 
2
injectable, 
cream 
pump

FLUTAMIDE
1
tablets
 - prostate cancer
GEMCITABINE
2
injectable
Advanced or metastatic 
non-small cell lung cancer 
 - prescribing limited to 
written authorization by 
physicians recommended by 
the lung tumour program

2
injectable
Bladder Cancer 
 - Gemcitabine/Cisplatin as 
first line chemotherapy in 
locally advanced/metastatic 
bladder cancer 
 - prescribing limited to 
written authorization by 
physicians recommended by 
the GU tumour program

2
injectable
Pancreas 
 - locally advanced or 
metastatic adenocarcinoma 
of the pancreas 
 - prescribing limited to 
written authorization by 
physicians recommended by 
the GI tumour program

2
injectable
Hematology 
 - Gemcitabine, 
Dexamethasone, Cisplatin 
for relapsed or refractory 
Hodgkins or Non-Hodgkins 
Lymphoma (GDP regimen) 
 - prescribing limited to 
written authorization by 
named physicians as 
recommended by the 
hematology/lymphoma 
program

2
injectable
Breast Cancer 
- Gemcitabine/Paclitaxel for 
treatment of metastatic breast 
cancer 
- prescribing limited to 
written authorization by 
named physicians as 
recommended by the breast 
tumour program

3
injectable
Hematology 
- Gemcitabine with 
Vinorelbine for recurrent or 
refractory Hodgkins 
Lymphoma (Pediatric COG 
Study Protocol AHOD0321) 
- prescribing limited to 
written authorization of 
named physicians as 
recommended by the 
pediatric tumour program
GOSERELIN
1
injectable
 - prostate cancer 
 - Restricted to: 
Stage II (T2a-T2c): 
Neoadjuvant use pre RT (2 
months pre and during RT). 
Neoadjuvant use pre radical 
prostatectomy (4 months pre) 
Stage III (T3a-T4b): 
Neoadjuvant use pre RT (2 
months pre and during RT). 
Adjuvant use (3 years post 
RT)



Stage IV (N1-N3) 
(M1-M1c): As monotherpy 
in medical castration 
In total androgen blockade 
(medical castration and 
nonsteriodal antiandrogen)



 - Guidelines for LHRH use 
in the above stated stages 
include: LHRH agonists are 
indicated for use in patients 
at risk of thromboembolic 
disease, strokes (CVA), 
myocardial infarction and 
also for consideration in 
patients with dyslipidemia, 
hypertension, diabetes 
mellitus or where a patient is 
considered intolerant to 
cyproterone acetate or 
megestrol acetate

2
injectable
 - breast cancer. 2nd line 
hormonal therapy for 
recurrent or metastatic 
disease in either or both 
estrogen and progesterone 
receptor positive pre and 
perimenopausal patients after 
tamoxifen failure 
 - prescribing limited to 
written authorization by 
physicians recommended by 
the breast tumour program

2
injectable
- breast cancer adjuvant 
- Goserelin, with or without 
Tamoxifen, as first line 
adjuvant treatment in pre or 
peri-menopausal patients 
with early hormone receptor 
positive breast cancer in 
whom chemotherapy is 
contraindicated 
- prescribing limited to 
written authorization by 
named physicians as 
recommended by the breast 
tumour program
HYDROCORTISONE SODIUM 
SUCCINATE 

1
injectable
- intrathecal use only
HYDROXYUREA
1
capsules

IDARUBICIN
3
injectable
POG Protocol 9720
- prescribing limited to 
written authorization by 
physicians recommended by 
the pediatric tumour program
IFOSFAMIDE
1 
2
injectable 
pump

IMATINIB
2
capsules
 - for surgically unresectable 
or metastatic gastrointestinal 
stromal tumour (GIST) 
 - prescribing limited to 
written authorization by 
named physicians as 
recommended by the tumour 
program

2
capsules
Hematology 
 - Philadelphia-chromosome 
positive leukemia (including 
disease situations such as 
first chronic phase chronic 
myelogenous leukemia 
(CML), accelerated phase 
CML, blast crisis phase 
CML, acute lymphoblastic 
leukemia, or other leukemias 
that have the characteristic 
t(9;22) translocation detected 
by cytogenetics, FISH 
analysis, or PCR-positive for 
bcr-abl oncogene)



 - prescribing limited to 
written authorization by 
named physicians as 
recommended by the 
hematology/lymphoma 
program
INTERFERON alpha 2b 

1
injectable
 - cladribine-resistant hairy 
cell leukemia 
 - Kaposi's sarcoma 
 - chronic myelogenous 
leukemia 
 - metastatic renal cell 
carcinoma

1
injectable
 - mycosis fungoides and 
sezary syndrome (cutaneous 
T-cell lymphomas) 
 - prescribing limited to 
written authorization by 
physicians recommended by 
the hematology/lymphoma 
tumour program

1
injectable
- basal cell carcinoma 
 - adjuvant treatment of high 
risk melanoma

1
injectable
Superficial Bladder Cancer 
 - Interferon alone - second 
line treatment or first line in 
those with a documented 
intolerance or 
contraindication (i.e., 
immunosuppression or other) 
to BCG 
 - Interferon in combination 
with BCG - second line 
treatment

2
injectable
 - treatment of patients with 
malignant carcinoid and 
neuroendocrine 
gastroenteropancreatic 
tumours not amenable to 
surgical extirpation 
 - prescribing limited to 
written authorization by 
physicians recommended by 
the GI and endocrine tumour 
programs

2
injectable
 - maintenance therapy in 
multiple myeloma patients 
who have achieved complete 
remission after high dose 
chemotherapy and 
autologous stem cell 
transplant



 - follicular lymphoma and 
need for therapy as indicated 
by any of: mass >7 cm or 3 
sites >3 cm, Bsx, 
splenomegaly @ umbilicus, 
compression syndromes (GI, 
GU, orbit), effusions 
cytopenias, Age < 70 yo



 - prescribing limited to 
written authorization by 
physicians recommended by 
the hematology/lymphoma 
tumour program

2
injectable
- for patients with 
polycythemia vera (PV) and 
essential thrombocythemia 
(ET):



a) PV-history of thrombosis, 
pruritis, or are over 40 years 
of age and who are 
intolerant, treatment resistant 
or have contraindication to 
alternative agents such as 
pregnancy (hydroxyurea) or 
cardiac disease (anagrelide



b) ET- history of thrombosis, 
pruritis or are over 60 years 
of age and who are 
intolerant, treatment resistant 
or have contraindications to 
cytotoxic agents such as 
pregnancy (hydroxyurea) or 
cardiac disease (anagrelide)



- prescribing limited to 
written authorization of 
named physicians as 
recommended by the 
hematology tumour program
IRINOTECAN 
 
*  NOTE: 
Loperamide supplied by industry 
with this agent's use
2
injectable
Metastatic Colorectal Cancer 
 - first line (with 5FU and 
leucovorin) 
 - 2nd line after failure of 
thymidilate synthase 
inhibitors (e.g., 5 
fluorouracil, raltitrexed, or 
capecitabine) 
 - prescribing limited to 
written authorization by 
physicians recommended by 
the GI tumour program

2
injectable
Pediatrics 
 - restricted to the treatment 
of high risk metastatic 
rhabdomyosarcomas 
following POG/CCG 
protocols 
 - prescribing limited to 
written authorization by 
physicians recommended by 
the pediatric tumour program
LETROZOLE
1
tablets
 - first line therapy for 
hormone receptor positive 
post-menopausal metastatic 
breast cancer
LEUCOVORIN CALCIUM
1
injectable, 
tablets
 - rescue therapy for 
methotrexate only 
 - in combination with 5FU
LEUPROLIDE
1
injectable
 - prostate cancer 
 - Restricted to: 
Stage II (T2a-T2c): 
Neoadjuvant use pre RT (2 
months pre and during RT). 
Neoadjuvant use pre radical 
prostatectomy (4 months pre) 
Stage III (T3a-T4b): 
Neoadjuvant use pre RT (2 
months pre and during RT). 
Adjuvant use (3 years post 
RT)



Stage IV (N1-N3) 
(M1-M1c): As monotherpy 
in medical castration. 
In total androgen blockade 
(medical castration and 
nonsteriodal antiandrogen)



- Guidelines for LHRH use 
in the above stated stages 
include: LHRH agonists are 
indicated for use in patients 
at risk of thromboembolic 
disease, strokes (CVA), 
myocardial infarction and 
also for consideration in 
patients with dyslipidemia, 
hypertension, diabetes 
mellitus or where a patient is 
considered intolerant to 
cyproterone acetate or 
megestrol acetate
LOMUSTINE
1
capsules

MECHLORETHAMINE
1
injectable, 
topical

MEDROXYPROGESTERONE 
ACETATE
1
tablets, 
injectable 


MEGESTROL ACETATE
1
tablets

MELPHALAN
1
tablets

MERCAPTOPURINE
1
tablets

MESNA
1
injectable

METHOTREXATE
1
injectable, 
tablets

MITOMYCIN
1
injectable
NOTE:  3rd line for bladder 
cancer indication
MITOXANTRONE
1
injectable

NANDROLONE DECANOATE
1
injectable

NILUTAMIDE
1
tablets
 - prostate cancer
PACLITAXEL
2
injectable
Ovarian Cancer 
 - first line treatment of 
ovarian cancer (irrespective 
of the stage of disease or 
amount of residual disease), 
fallopian tube carcinoma, 
primary peritoneal neoplasms 
and papillary serous and 
clear cell endometrial 
carcinomas



 - prescribing limited to 
written authorization by 
physicians recommended by 
the gynecology tumour 
program

2
injectable
Endometrial Cancer 
 - restricted for use in 
metastatic, advanced or 
recurrent endometrial cancer 
 - prescribing limited to 
written authorization by 
named physicians as 
recommended by the 
gynecology tumour program

2
injectable
Lung Cancer 
 - prescribing limited to 
written authorization by 
physicians recommended by 
the lung tumour program

2
injectable
Adjuvant Chemotherapy in 
NSCLC 
- Vinorelbine (with 
Cisplatin) or Paclitaxel (with 
Carboplatin) for Adjuvant 
treatment of Non Small Cell 
Lung Cancer (NSCLC) stage 
IB-II 
- prescribing limited to 
written authorization by 
physicians recommended by 
the lung tumour program

2
injectable
Breast Cancer 
 - restricted to the treatment 
of metastatic breast cancer 
when no response to 
anthracycline (doxorubicin, 
epirubicin, or mitoxantrone) 
containing regimen. Relapse 
within 1 year after 
completion of adjuvant 
chemotherapy including an 
anthracycline. First 
assessment of efficacy after 2 
courses



 - only one taxane is to be 
administered to any one 
patient



- prescribing limited to 
written authorization by 
physicians recommended by 
the breast tumour program

2
injectable
Breast Cancer Adjuvant 
 - Doxorubicin/ 
Cyclophosphamide followed 
by Paclitaxel as an option for 
adjuvant therapy of Stage II, 
node positive or high risk 
node negative breast cancer 
 - prescribing limited to 
written authorization by 
named physicians as 
recommended by the breast 
tumour program

2
injectable
Testes 
 - 2nd line regimen for 
relapsed germ cell tumours 
of the testes

2
injectable
 - in combination 
chemotherapy for unknown 
primary metastatic 
adenocarcinoma 
 - prescribing limited to 
written authorization by 
named physicians as 
recommended by the breast 
and hematology tumour 
programs

3
injectable
Breast Cancer Adjuvant 
- Epirubicin/Cyclophos-
phamide followed by 
Paclitaxel for patients treated 
on the experimental arm of 
NCIC clinical trial MA 21



- prescribing limited to 
written authorization by a 
clinical trial principal 
investigator or 
co-investigator
PAMIDRONATE
1
injectable
- treatment of multiple 
myeloma
PEMETREXED
2
injectable
- Pemetrexed (in 
combination with Cisplatin) 
for use in patients with 
malignant mesothelioma 
- prescribing limited to 
written authorization of 
named physicians as 
recommended by the lung 
tumour program
PREDNISOLONE SODIUM 
PHOSPHATE
1
liquid
- first line agent for pediatric 
patients under 7 years of age 
- 2nd-line agent for pediatric 
patients 7 years and older 
unable to tolerate prednisone 
tablets
PREDNISONE
1
tablets

PROCARBAZINE
1
capsules

RALTITREXED
2
injectable
- treatment of metastatic 
colorectal cancer 
 - prescribing limited to 
written authorization by 
physicians recommended by 
the GI tumour program
RITUXIMAB
2
injectable
- Rituximab plus 
chemotherapy for patients 
with follicular, mantle cell, 
and other CD20 positive 
indolent histology 
non-Hodgkin's lymphoma 
who have had no prior 
treatment with rituximab



 - relapsed or refractory, low 
grade or follicular, CD 20 
positive, B-cell, 
non-Hodgkin's  lymphoma



- prescribing limited to 
written authorization by 
physicians recommended by 
the lymphoma tumour 
program

2
injectable
- in combination with CHOP 
for aggressive histology 
B-cell CD20 positive 
non-Hodgkin's lymphoma 
(any stage or age) 
- prescribing limited to 
written authorization by 
named physicians as 
recommended by the 
hematology/lymphoma 
tumour program

2
injectable
 - for Post Transplant 
Lymphoproliferative 
Disorders (PTLD) 
- prescribing limited to 
written authorization by 
named physicians as 
recommended by the 
hematology tumour program
STREPTOZOCIN
1
injectable

TAMOXIFEN
1
tablets

TEMOZOLOMIDE
2
oral
 - first line treatment of 
recurrent glioblastoma 
multiforme and anaplastic 
astrocytoma 
- first line concurrent (with 
RT)/adjuvant treatment for 
malignant glioma 
- prescribing limited to 
written authorization by 
physicians recommended by 
the neuro oncology tumour 
program
TENIPOSIDE
1
injectable

THIOGUANINE
1
tablets

TOPOTECAN
2
injectable
Ovarian 
- 2nd line therapy of ovarian 
cancer, fallopian tube 
carcinoma and primary 
peritoneal neoplasms 
- prescribing limited to 
written authorization by 
physicians recommended by 
the gynecology tumour 
program



Pediatrics 
- restricted to the treatment 
of advanced stage 
neuroblastoma following 
POG/CCG Protocols 
- restricted to the treatment 
of intermediate risk 
rhabdomyosarcoma 
following POG/CCG 
protocols



- prescribing limited to 
written authorization by 
physicians recommended by 
the pediatric tumour program
TRASTUZUMAB
2
injectable
Metastatic Breast 
- restricted to the treatment 
of metastic breast cancer, 
HER 2 protein 
overexpression (+3) by IHC, 
or HER 2 amplification by 
FISH 
- prescribing limited to 
written authorization by 
physicians recommended by 
the breast tumour program
VALRUBICIN
2
injectable
 - for BCG refractory 
carcinoma in situ, defined as 
persistent disease after 2 
courses of BCG or 
intolerance (severe side 
effects, immunosuppression, 
etc.) to treatment with BCG
VINBLASTINE
1
injectable

VINCRISTINE
1
injectable

VINORELBINE
2
injectable
Lung Cancer 
- restricted to the treatment 
of advanced or metastatic 
non-small cell lung cancer 
with an ECOG score of 2 or 
better 
- prescribing limited to 
written authorization by 
physicians recommended by 
the lung tumour program

2
injectable
Metastatic Breast 
- first-line therapy for elderly 
patients (over 65 years of 
age) and 2nd or 3rd line 
therapy for metastatic breast 
cancer.  Assess response 
after 2 cycles 
- prescribing limited to 
written authorization by 
physicians recommended by 
the breast tumour program

2
injectable
Adjuvant Chemotherapy in 
NSCLC 
- Vinorelbine (with 
Cisplatin) or Paclitaxel (with 
Carboplatin) for Adjuvant 
treatment of Non Small Cell 
Lung Cancer (NSCLC) Stage 
IB/II 
- prescribing limited to 
written authorization by 
physicians recommended by 
the lung tumour program



--------------------------------
Alberta Regulation 19/2005
Cancer Programs Act
CANCER PROGRAMS AMENDMENT REGULATION
Filed: February 22, 2005
For information only:   Made by the Minister of Health and Wellness (M.O. 2/2005) 
on February 17, 2005 pursuant to sections 22 and 38 of the Cancer Programs Act. 
1   The Cancer Programs Regulation (AR 242/98) is 
amended by this Regulation.

2   Section 1 is amended
	(a)	in subsection (1)
	(i)	by repealing clause (e);
	(ii)	in clause (g)
	(A)	by repealing subclause (ii) and 
substituting the following:
	(ii)	is registered in the Cancer Registry with a 
disease classified in the International 
Classification of Diseases for Oncology 
referred to in subsection (2),
	(B)	by repealing subclause (v) and 
substituting the following:
	(v)	is an inpatient or outpatient of a cancer 
hospital, clinic or program operated by the 
board;
	(iii)	by repealing clause (h);
	(iv)	by adding the following after clause (j):
	(k)	"Schedule" means the schedule of cancer drugs 
established pursuant to section 16.1 of the Act.
	(b)	in subsection (2) by striking out "classified as 
malignant, in situ or metastatic".

3   Section 3(a) is amended
	(a)	by repealing subclause (ii) and substituting the 
following:
	(ii)	gender;
	(b)	by adding the following after subclause (xii):
	(xiii)	place, date and cause of death;

4   Section 5 is amended by striking out "specified by the 
Minister".

5   Section 6 is repealed and the following is added:
Group 1 cancer drugs
6(1)  Cancer drugs in group 1 of the Schedule may be initially 
provided by a Board Pharmacy for 30 days pursuant to a 
prescription written by a person who is authorized by the board to 
prescribe cancer drugs and who is a physician, a regulated member 
under the Health Professions Act authorized to prescribe drugs or a 
person authorized to prescribe drugs pursuant to another 
enactment.
(2)  If an eligible member of the board medical staff reviews the 
initial prescription referred to in subsection (1) and approves the 
prescription, the Board Pharmacy may continue to provide the 
prescribed cancer drugs.

6   Section 7 is amended by striking out "a physician" and 
substituting "a person authorized by the board to prescribe cancer 
drugs and who is a physician, a regulated member under the Health 
Professions Act authorized to prescribe drugs or a person authorized to 
prescribe drugs pursuant to another enactment".

7   Section 8(b) is amended by striking out "emergency release 
by the Health Protection Branch of" and substituting "special 
access by".

8   Section 10(a) is repealed and the following is 
substituted:
	(a)	administered directly to patients of cancer hospitals, clinics 
or programs operated by the board, or

9   Section 13 is amended by striking out "October 31, 2013" 
and substituting "September 30, 2014".

10   The Schedule is repealed.

11   Sections 2(a)(iv) and 10 come into force on the coming 
into force of section 3 of the Miscellaneous Statutes 
Amendment Act, 2003 (No. 2).



Alberta Regulation 20/2005
Teachers' Pension Plans Act
TEACHERS' PENSION PLANS (LEGISLATIVE PROVISIONS) 
(RELATIONSHIP BREAKDOWN EXTENSION 2005) 
AMENDMENT REGULATION
Filed: February 23, 2005
For information only:   Made by the Lieutenant Governor in Council (O.C. 101/2005) 
on February 23, 2005 pursuant to section 23 of the Teachers' Pension Plans Act. 
1   The Teachers' Pension Plans (Legislative Provisions) 
Regulation (AR 204/95) is amended by this Regulation.

2   Section 17(3) is amended by striking out "2005" and 
substituting "2006".





THE ALBERTA GAZETTE, PART II, MARCH 15, 2005